Biogen Company Profile (NASDAQ:BIIB)

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Biogen Inc (NASDAQ:BIIB) issued its earnings results on Tuesday, April, 25th. The company reported $5.20 earnings per share for the quarter, beating the Zacks' consensus estimate of $4.97 by $0.23. The firm had revenue of $2.81 billion for the quarter, compared to the consensus estimate of $2.73 billion. Biogen had a return on equity of 38.48% and a net margin of 32.34%. The company's revenue was up 3.1% compared to the same quarter last year. During the same quarter last year, the business posted $4.79 EPS. View Biogen's Earnings History.

Biogen is scheduled to release their next quarterly earnings announcement on Wednesday, July, 19th 2017. View Earnings Estimates for Biogen.

23 brokerages have issued 12 month price objectives for Biogen's stock. Their forecasts range from $277.00 to $442.00. On average, they expect Biogen's share price to reach $332.10 in the next year. View Analyst Ratings for Biogen.

Here are some recent quotes from research analysts about Biogen stock:

• 1. Cantor Fitzgerald analysts commented, "A German patient treated for three years with Tysabri and then with a single dose of Ocrevus developed PML." (5/25/2017)
• 2. Cowen and Company analysts commented, "Biogen reported Q1 revenues of $2.81B (+3% Y/Y, vs. consensus of $2.74B) and non-." (4/25/2017)
• 3. Mizuho analysts commented, "We just started our Spinraza webinar … here’s a link to the slides pdf Rating Neutral Previous Rating No Change Price (4/17) $274.05 Price Target $290.00 Previous Price Target No Change LINK to slides for our Spinraza webinar (for folks who prefer a pdf copy): CLICK HERE Link to join webinar (just started): CLICK HERE We intend to blast a replay of the webinar after we finish. PLEASE REFER TO PAGE 3 OF THIS REPORT FOR IMPORTANT DISCLOSURE AND ANALYST CERTIFICATION INFORMATION. Mizuho Securities USA LLC does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision." (4/18/2017)
• 4. Instinet analysts commented, "We are initiating on BIIB with a Buy rating and $345 target price. We recommend owning BIIB shares over the next 12 months given limited 2017 downside to revenue forecasts and potential Spinraza launch upside. We estimate that a successful Spinraza launch will drive above-consensus revenues of $11.6bn in 2017 and $12.2bn in 2018, despite flat MS-franchise growth that may be impacted by emerging competition (Ocrevus). We anticipate this return to growth will drive modest revenue multiple expansion and strong GAAP EPS growth - to $19.41 in 2017 and $21.56 in 2018, yielding upside to our $345 target price." (3/1/2017)
• 5. Jefferies Group LLC analysts commented, "This morning BIIB announced a settlement with FWP around Tecfidera IP. While we believe Street expectations were generally balanced going into the 3/17 decision (and we had assumed 50/50 prob. BIIB would be successful), commercial and some IPR risk remains, and recent focus has been more on Spinraza launch and Alzheimer’s, the terms look reasonable to us and help reduce an overhang." (1/18/2017)

Some companies that are related to Biogen include Celgene (CELG), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Grifols SA, Barcelona (GRFS), Incyte (INCY), Illumina (ILMN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Seattle Genetics (SGEN), Jazz Pharmaceuticals plc - (JAZZ), TESARO (TSRO), Alnylam Pharmaceuticals (ALNY), Exelixis (EXEL), BIO-TECHNE Corp (TECH), Kite Pharma (KITE), Galapagos NV (GLPG) and Opko Health (OPK).

Biogen's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.34%), Primecap Management Co. CA (7.30%), Vanguard Group Inc. (6.77%), State Street Corp (4.52%), Wellington Management Group LLP (2.69%) and FMR LLC (2.61%). Company insiders that own Biogen stock include Adam Koppel, Adriana Karaboutis, Alexander J Denner, Alfred Sandrock, Caroline Dorsa, Douglas E Williams, George A Scangos, Michel Vounatsos, Paul J Clancy, Robert W Pangia and Stelios Papadopoulos. View Institutional Ownership Trends for Biogen.

Biogen's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Ameriprise Financial Inc., Parametric Portfolio Associates LLC, SG Americas Securities LLC, Korea Investment CORP, William Blair Investment Management LLC, Wellington Management Group LLP and Primecap Management Co. CA. Company insiders that have sold Biogen stock in the last year include Adam Koppel, Adriana Karaboutis, Alfred Sandrock, Caroline Dorsa, George A Scangos, Paul J Clancy and Robert W Pangia. View Insider Buying and Selling for Biogen.

Biogen's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Janus Capital Management LLC, Massachusetts Financial Services Co. MA, Winslow Capital Management LLC, AQR Capital Management LLC, Lazard Asset Management LLC, Westfield Capital Management Co. LP and Vanguard Group Inc.. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner, Michel Vounatsos and Stelios Papadopoulos. View Insider Buying and Selling for Biogen.

Shares of Biogen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Biogen stock can currently be purchased for approximately $250.80.